{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Maurer-Granofszky M"],"funding":["European Union’s H2020 Research and Innovation Program"],"pagination":["6148"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8656726"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(23)"],"pubmed_abstract":["Monitoring of minimal residual disease (MRD) by flow cytometry (FCM) is a powerful prognostic tool for predicting outcomes in acute lymphoblastic leukemia (ALL). To apply FCM-MRD in large, collaborative trials, dedicated laboratory staff must be educated to concordantly high levels of expertise and their performance quality should be continuously monitored. We sought to install a unique and comprehensive training and quality control (QC) program involving a large number of reference laboratories within the international Berlin-Frankfurt-Münster (I-BFM) consortium, in order to complement the standardization of the methodology with an educational component and persistent quality control measures. Our QC and quality assurance (QA) program is based on four major cornerstones: (i) a twinning ma"],"journal":["Cancers"],"pubmed_title":["An Extensive Quality Control and Quality Assurance (QC/QA) Program Significantly Improves Inter-Laboratory Concordance Rates of Flow-Cytometric Minimal Residual Disease Assessment in Acute Lymphoblastic Leukemia: An I-BFM-FLOW-Network Report."],"pmcid":["PMC8656726"],"funding_grant_id":["26.01.2019 / 42/772","825749 "CLOSER""],"pubmed_authors":["Svec P","Felice M","Carelli D","Rossi J","Barcala V","Giordano H","Ratei R","Slavkovic B","Bukowska-Strakova K","Kloboves Prevodnik V","Maurer-Granofszky M","Taparkou A","Basso G","Hevessy Z","Schrappe M","Galeano A","Kohlscheen S","Malusardi C","Attarbaschi A","Kreminska E","Hrusak O","Moller C","Martin BM","Sedek L","Agriello E","Jakso P","Batinic D","Paterakis G","Nikulshin S","Mejstrikova E","Anastasiou-Grenzelia T","Torrebadell M","Scarparo P","Dubravcic K","Solari L","Maglia O","Gonzalez A","Dworzak MN","Popov A","Deniz G","Palazzi J","Rodriguez C","Karawajew L","Groeneveld-Krentz S","Tzanoudaki M","Suzan AC","Biondi A","Samardzija G","Varotto E","Gaillard MI","Barna G","Bruggemann M","Burnusuzov H","Gaipa G","Sartor M","Marinov N","On Behalf Of I-Bfm-Flow-Network","Campbell M","Schumich A","Bourquin JP","Buldini B","Sajaroff EO","Kappelmayer J","Kiss C","Feuerstein T","Iarossi MB","Vernitsky H","Conter V","Sala S","Szczepanski T"],"additional_accession":[]},"is_claimable":false,"name":"An Extensive Quality Control and Quality Assurance (QC/QA) Program Significantly Improves Inter-Laboratory Concordance Rates of Flow-Cytometric Minimal Residual Disease Assessment in Acute Lymphoblastic Leukemia: An I-BFM-FLOW-Network Report.","description":"Monitoring of minimal residual disease (MRD) by flow cytometry (FCM) is a powerful prognostic tool for predicting outcomes in acute lymphoblastic leukemia (ALL). To apply FCM-MRD in large, collaborative trials, dedicated laboratory staff must be educated to concordantly high levels of expertise and their performance quality should be continuously monitored. We sought to install a unique and comprehensive training and quality control (QC) program involving a large number of reference laboratories within the international Berlin-Frankfurt-Münster (I-BFM) consortium, in order to complement the standardization of the methodology with an educational component and persistent quality control measures. Our QC and quality assurance (QA) program is based on four major cornerstones: (i) a twinning ma","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Dec","modification":"2025-04-26T09:32:00.024Z","creation":"2022-02-11T15:21:28.786Z"},"accession":"S-EPMC8656726","cross_references":{"pubmed":["34885257"],"doi":["10.3390/cancers13236148"]}}